1. Search Result
Search Result
Results for "

Na _HCO3- Cotransporter

" in MedChemExpress (MCE) Product Catalog:

307

Inhibitors & Agonists

2

Screening Libraries

6

Fluorescent Dye

14

Biochemical Assay Reagents

27

Peptides

1

MCE Kits

46

Natural
Products

88

Recombinant Proteins

30

Isotope-Labeled Compounds

6

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15529

    Na+/HCO3- Cotransporter Cardiovascular Disease
    S0859 is a selective, high-affinity generic Na +/HCO3 - transporter (NBC) inhibitor. S0859 reversibly inhibits NBC-mediated intracellular pH (pHi) recovery (Ki=1.7 μM, full inhibition at approximately 30 μM).
    S0859
  • HY-154912

    Others Inflammation/Immunology
    PAT1inh-B01 is a selective SLC26A6 inhibitor. PAT1inh-B01 inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 blocks fluid absorption in small intestine. PAT1inh-B01 can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01
  • HY-P2989

    Endogenous Metabolite Metabolic Disease
    Pyruvate carboxylase is a biotin-containing enzyme that catalyzes the HCO3 and MgATP dependent carboxylation of pyruvate to form oxaloacetate. Pyruvate carboxylase plays an essential role in controlling whole-body energetics through regulation of gluconeogenesis in the liver, synthesis of fatty acids in adipocytes, and insulin secretion in pancreatic β cells .
    Pyruvate carboxylase
  • HY-155482

    Others Neurological Disease
    NA-184 is a selective calpain-2 inhibitor. NA-184 inhibits TBI-induced cell death with an EC50 of 0.13 mg/kg .
    <em>NA</em>-184
  • HY-N10627

    Others Others
    NA2 Glycan is NA2 N-linked oligosaccharide. NA2 is the asialo-substructure of A2 glycan. NA2 glycan can be isolated from mammalian serum glycoproteins, such as serum IgG .
    <em>NA</em>2 Glycan
  • HY-17468A

    Ro 10-6338 sodium; PF 1593 sodium

    NKCC Cardiovascular Disease Metabolic Disease
    Bumetanide sodium, a highly potent loop diuretic, is a Na +-K +-Cl + cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively .
    Bumetanide sodium
  • HY-154912A

    Others Inflammation/Immunology
    PAT1inh-B01 hydrocholide is a selective SLC26A6 inhibitor. PAT1inh-B01 hydrocholide inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 hydrocholide blocks fluid absorption in small intestine. PAT1inh-B01 hydrocholide can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01 hydrochloride
  • HY-162455

    EAAT Others
    NA-014 (40) is a selective EAAT2 positive allosteric modulator (PAM), with an EC50 of 3 nM .
    <em>NA</em>-014
  • HY-109144

    DWP-16001

    SGLT Metabolic Disease
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor [3].
    Enavogliflozin
  • HY-19298

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    S-8921 is an ileal Na +/bile acid cotransporter (IBAT) inhibitor.
    S-8921
  • HY-161397

    Bacterial Infection Inflammation/Immunology
    NA-1-157 is a potent irreversible covalent inhibitor of the GES-5 carbapenemase, with a MIC of 0.5 μg/mL .
    <em>NA</em>-1-157
  • HY-17468
    Bumetanide
    3 Publications Verification

    Ro 10-6338; PF 1593

    NKCC Cardiovascular Disease Metabolic Disease
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na +-K +-Cl + cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively .
    Bumetanide
  • HY-B1604

    2-Chloroprocaine hydrochloride

    Na+/K+ ATPase Neurological Disease
    Chloroprocaine hydrochloride (2-Chloroprocaine hydrochloride) is a potent inhibitor of Na,K-ATPase activity with an IC50 of 13 mM. Chloroprocaine hydrochloride blocks peripheral nerve .
    Chloroprocaine hydrochloride
  • HY-B1604A

    2-Chloroprocaine

    Na+/K+ ATPase
    Chloroprocaine (2-Chloroprocaine) is a potent inhibitor of Na,K-ATPase activity with an IC50 of 13 mM. Chloroprocaine blocks peripheral nerve .
    Chloroprocaine
  • HY-B1039
    Ambroxol
    2 Publications Verification

    Na-872

    Glucosidase Autophagy Neurological Disease Metabolic Disease
    Ambroxol (NA-872), an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research .
    Ambroxol
  • HY-B1039A
    Ambroxol hydrochloride
    2 Publications Verification

    Na-872 hydrochloride

    Glucosidase Autophagy Neurological Disease Metabolic Disease
    Ambroxol hydrochloride (NA-872 hydrochloride), an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol hydrochloride is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol hydrochloride induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research .
    Ambroxol hydrochloride
  • HY-160656

    5-HT Receptor Neurological Disease
    5-HT/NA Reuptake inhibitor-1 (compound 9) is a selective dual 5-HT and NA reuptake inhibitor with IC50 of 660 nM and 70 nM respectively. . 5-HT/NA Reuptake inhibitor-1 has good in vitro human metabolic stability, hERG selectivity and passive membrane permeability .
    5-HT/<em>NA</em> Reuptake inhibitor-1
  • HY-140340

    PROTAC Linkers Cancer
    Fmoc-NH-pentanoic acid-NHS-SO3Na is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs .
    Fmoc-NH-pentanoic acid-NHS-SO<em>3</em><em>Na</em>
  • HY-B1039AR

    Na-872 hydrochloride (Standard)

    Glucosidase Autophagy Neurological Disease Metabolic Disease
    Ambroxol (hydrochloride) (Standard) is the analytical standard of Ambroxol (hydrochloride). This product is intended for research and analytical applications. Ambroxol hydrochloride (NA-872 hydrochloride), an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol hydrochloride is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol hydrochloride induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research .
    Ambroxol hydrochloride (Standard)
  • HY-B1039C

    Na-872 (acefylline); Acebrophylline

    Glucosidase Autophagy Neurological Disease Metabolic Disease
    Ambroxol (NA-872) acefylline, an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol acefylline is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol acefylline induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research .
    Ambroxol (acefylline)
  • HY-P1920

    EBV Inflammation/Immunology
    CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .
    CEF19, Epstein-Barr Virus latent <em>NA</em>-<em>3</em>A (458-466)
  • HY-B1039AS

    Na-872-d5 hydrochloride

    Isotope-Labeled Compounds Glucosidase Autophagy Neurological Disease Metabolic Disease
    Ambroxol-d5 (hydrochloride) is the deuterium labeled Ambroxol hydrochloride. Ambroxol hydrochloride (NA-872 hydrochloride), an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol hydrochloride is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol hydrochloride induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research[1][2].
    Ambroxol-d5 hydrochloride
  • HY-151104

    Influenza Virus Infection
    Neuraminidase-IN-11 (15e) is a potent and selective neuraminidase (NA) inhibitor with the IC50 values of 4.7 nM, 8.46 nM and 1.5 nM against H1N1, H5N1 and H5N8 NAs respectively .
    Neuraminidase-IN-11
  • HY-Y1889A

    CMC-Na (MW 250000); CMC-Na (Viscosity:1500-3100 mPa.s)

    Biochemical Assay Reagents Others
    Sodium carboxymethyl cellulose (CMC-Na) (MW 250000) is a sodium salt of carboxymethyl cellulose. Sodium carboxymethyl cellulose has adsorption and corrosion inhibition on low-carbon steel in an acidic medium. Sodium carboxymethyl cellulose can be used as a thickener, paste and barrier agent [3].
    Sodium carboxymethyl cellulose (MW 250000)
  • HY-13941B
    1-Naphthyl PP1 hydrochloride
    1 Publications Verification

    1-Na-PP 1 hydrochloride

    Src Cancer
    1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
    1-Naphthyl PP1 hydrochloride
  • HY-103332

    Na-Gly

    GlyT Endogenous Metabolite Inflammation/Immunology
    N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .
    N-Arachidonylglycine
  • HY-13941
    1-Naphthyl PP1
    1 Publications Verification

    1-Na-PP 1

    Src PKD Cancer
    1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively [3].
    1-Naphthyl PP1
  • HY-106158

    SGLT Metabolic Disease
    T-1095 is a selective and orally active Na +-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .
    T-1095
  • HY-P2660

    GD4K-Na

    Enteropeptidase Others
    Gly-Asp-Asp-Asp-Asp-Lys-β-naphthylamide (GD4K-na) is a substrate for human enteropeptidase (Km: 0.16 mM) .
    Gly-Asp-Asp-Asp-Asp-Lys-β-naphthylamide
  • HY-17468R

    Ro 10-6338 (Standard); PF 1593 (Standard)

    NKCC Cardiovascular Disease Metabolic Disease
    Bumetanide (Standard) is the analytical standard of Bumetanide. This product is intended for research and analytical applications. Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na +-K +-Cl + cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively .
    Bumetanide (Standard)
  • HY-P0117
    Tat-NR2B9c
    5+ Cited Publications

    Tat-NR2Bct; Na-1

    iGluR NO Synthase Neurological Disease
    Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c
  • HY-15409
    Empagliflozin
    Maximum Cited Publications
    50 Publications Verification

    BI 10773

    SGLT Metabolic Disease
    Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2 .
    Empagliflozin
  • HY-100322

    Chloride Channel Cardiovascular Disease
    H100 is a Cl - transport inhibitor, with partial effects against both the NaK2Cl cotransporter and the Band 3 anion exchanger, but no effect against KCl cotransporter, in human erythrocytes.
    H100
  • HY-B0135
    Furosemide
    2 Publications Verification

    NKCC GABA Receptor Metabolic Disease Cancer
    Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
    Furosemide
  • HY-B0135A
    Furosemide sodium
    2 Publications Verification

    NKCC GABA Receptor Metabolic Disease Cancer
    Furosemide sodium is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
    Furosemide sodium
  • HY-14945

    GSK189075

    SGLT Metabolic Disease
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
    Remogliflozin etabonate
  • HY-15409S

    BI 10773-d4

    SGLT Metabolic Disease
    Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].
    Empagliflozin-d4
  • HY-109092
    Licogliflozin
    1 Publications Verification

    LIK066

    SGLT Metabolic Disease Inflammation/Immunology
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
    Licogliflozin
  • HY-B0135S

    NKCC GABA Receptor Metabolic Disease Cancer
    Furosemide-d5 is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2[1]. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].
    Furosemide-d5
  • HY-B0135R

    NKCC GABA Receptor Metabolic Disease Cancer
    Furosemide (Standard) is the analytical standard of Furosemide. This product is intended for research and analytical applications. Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl -?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
    Furosemide (Standard)
  • HY-109018
    Velagliflozin
    1 Publications Verification

    SGLT Metabolic Disease
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
    Velagliflozin
  • HY-124738

    Sodium Channel Metabolic Disease
    BI 01383298 is a potent inhibitor of the sodium-citrate co-transporter (SLC13A5) that is highly expressed in the liver .
    BI 01383298
  • HY-116223

    SGLT Metabolic Disease
    Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes .
    Tianagliflozin
  • HY-137145

    SGLT Others
    Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM .
    galacto-Dapagliflozin
  • HY-126831

    Fluorescent Dye Others
    SBFI-AM is a Na + selective fluorescent indicator. SBFI-AM shows selectivity for Na + over K + .
    SBFI-AM
  • HY-112065
    PF-06869206
    1 Publications Verification

    Sodium Channel Metabolic Disease
    PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM .
    PF-06869206
  • HY-W040263

    TAPS Na

    Biochemical Assay Reagents Others
    TAPS sodium is a biological buffer that protects the structural integrity of lysozyme bacteria and prevents them from thermal denaturation at high temperatures. A pKa of 8.1 for TAPS results in half-maximal connexin channel activity .
    TAPS sodium
  • HY-131899

    Potassium Channel Sodium Channel Others
    N-Bromoacetamide can irreversibly remove sodium channel inactivation in the cytoplasmic face of the membrane, also decreasing K current rapid inactivation .
    N-Bromoacetamide
  • HY-19062

    Calcium Channel Na+/Ca2+ Exchanger Cardiovascular Disease
    SM-6586 is a calcium channel antagonist and inhibitor of Na +/H + and Na +/Ca 2+ exchange transport, potentially for the treatment of cerebrovasular diseases and hypertension.
    SM-6586
  • HY-124925

    (-)-IsoeburNamine; (-)-epi-EburNamine

    Sodium Channel Neurological Disease
    Vincanol ((-)-Isoeburnamine) is a blocker of voltage-gated Na+ channels. Vincanol blocks Na + currents with an IC50 value of 40 μM. Vincanol has neuroprotective effect .
    Vincanol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: